Breast cancer resistance protein (BCRP) and sulfotransferases contribute significantly to the disposition of genistein in mouse intestine

AAPS Journal

Volumn 12, Issue 4, 2010, Pages 525-536

  Zhu, Wei ^a   Xu, Haiyan ^a   Wang, Stephen W J ^a   Hu, Ming ^a  

^a UNIVERSITY OF HOUSTON   (United States)

Author keywords

Breast cancer resistance protein (BCRP); Efflux transporters; Genistein; Multidrug resistance protein 2 (MRP2); Sulfotransferases

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; EFFLUX TRANSPORTER; ESTRONE SULFATE; GENISTEIN; GLUCURONIDE; PRASTERONE SULFATE; SULFATE; SULFOTRANSFERASE; UNCLASSIFIED DRUG; VERLUKAST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL STRAIN CACO 2; COLON; CONTROLLED STUDY; DRUG DISPOSITION; DRUG EXCRETION; DUODENUM; GLUCURONIDATION; HYDROLYSIS; ILEUM; JEJUNUM; KNOCKOUT MOUSE; MALE; MOUSE; MUCOSA CELL; NONHUMAN; RAT;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GENISTEIN; INTESTINES; MALE; MICE; MICE, KNOCKOUT; RATS; SULFOTRANSFERASES;

EID: 78649639527     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-010-9209-x     Document Type: Article

References (35)

1. MS Kurzerand X Xu 1997 Dietary phytoestrogens Annu Rev Nutr 17 353 381 10.1146/annurev.nutr.17.1.353 (Pubitemid 27328805)
2. CA Lamartiniere MS Cotroneo WA Fritz J Wang R Mentor-Marcel A Elgavish 2002 Genistein chemoprevention: timing and mechanisms of action in murine mammary and prostate J Nutr 132 552S 558S 11880592 (Pubitemid 34208769)
3. F Cao TY Jin YF Zhou 2006 Inhibitory effect of isoflavones on prostate cancer cells and PTEN gene Biomed Environ Sci 19 35 41 16673816 1:CAS:528:DC%2BD28XkvValuro%3D
4. Y Gu CF Zhu H Iwamoto JS Chen 2005 Genistein inhibits invasive potential of human hepatocellular carcinoma by altering cell cycle, apoptosis, and angiogenesis World J Gastroenterol 11 6512 6517 16425425 1:CAS:528: DC%2BD28XhvVamt7c%3D
5. EJ Kim HK Shin JH Park 2005 Genistein inhibits insulin-like growth factor-I receptor signaling in HT-29 human colon cancer cells: a possible mechanism of the growth inhibitory effect of Genistein J Med Food 8 431 438 10.1089/jmf.2005.8.431 16379552 1:CAS:528:DC%2BD2MXhtlCntbrK
6. KD Setchell NM Brown P Desai L Zimmer-Nechemias BE Wolfe WT Brashear, et al. 2001 Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements J Nutr 131 1362S 1375S 11285356 1:CAS:528:DC%2BD3MXjsl2itb0%3D
7. MG Busby AR Jeffcoat LT Bloedon MA Koch T Black KJ Dix, et al. 2002 Clinical characteristics and pharmacokinetics of purified soy isoflavones: single-dose administration to healthy men Am J Clin Nutr 75 126 136 11756070 1:CAS:528:DC%2BD38XhslylsQ%3D%3D
8. A Gopalakrishnan CJ Xu SS Nair C Chen V Hebbar AN Kong 2006 Modulation of activator protein-1 (AP-1) and MAPK pathway by flavonoids in human prostate cancer PC3 cells Arch Pharm Res 29 633 644 10.1007/BF02968247 16964758 1:CAS:528:DC%2BD28XhtVCjtb3M
9. T Fotsis M Pepper H Adlercreutz G Fleischmann T Hase R Montesano, et al. 1993 Genistein, a dietary-derived inhibitor of in vitro angiogenesis Proc Natl Acad Sci USA 90 2690 2694 10.1073/pnas.90.7.2690 7681986 1:CAS:528: DyaK3sXit1Ggsrw%3D
10. SP Vermaand BR Goldin 1998 Effect of soy-derived isoflavonoids on the induced growth of MCF-7 cells by estrogenic environmental chemicals Nutr Cancer 30 232 239 10.1080/01635589809514669
11. Y Liuand M Hu 2002 Absorption and metabolism of flavonoids in the caco-2 cell culture model and a perused rat intestinal model Drug Metab Dispos 30 370 377 10.1124/dmd.30.4.370 (Pubitemid 34263820)
12. RA King JL Broadbent RJ Head 1996 Absorption and excretion of the soy isoflavone genistein in rats J Nutr 126 176 182 8558299 1:CAS:528: DyaK28Xlt1agug%3D%3D
13. G Rimbach PD Weinberg S de Pascual-Teresa MG Alonso BA Ewins R Turner, et al. 2004 Sulfation of genistein alters its antioxidant properties and its effect on platelet aggregation and monocyte and endothelial function Biochim Biophys Acta 1670 229 237 14980449 1:CAS:528:DC%2BD2cXht1Kmu74%3D
14. S Barnes J Sfakianos L Coward M Kirk 1996 Soy isoflavonoids and cancer prevention. Underlying biochemical and pharmacological issues Adv Exp Med Biol 401 87 100 8886128 1:CAS:528:DyaK28Xmt1Oisro%3D
15. CD Allred NC Twaddle KF Allred TS Goeppinger MI Churchwell YH Ju, et al. 2005 Soy processing affects metabolism and disposition of dietary isoflavones in ovariectomized BALB/c mice J Agric Food Chem 53 8542 8550 10.1021/jf051246w 16248551 1:CAS:528:DC%2BD2MXhtVKmtLnF (Pubitemid 41608911)
16. J Chen H Lin M Hu 2003 Metabolism of flavonoids via enteric recycling: role of intestinal disposition J Pharmacol Exp Ther 304 1228 1235 10.1124/jpet.102.046409 12604700 1:CAS:528:DC%2BD3sXit1eisL4%3D (Pubitemid 36254436)
17. J Chen H Lin M Hu 2005 Absorption and metabolism of genistein and its five isoflavone analogs in the human intestinal Caco-2 model Cancer Chemother Pharmacol 55 159 169 10.1007/s00280-004-0842-x 15455178 1:CAS:528: DC%2BD2cXhtVGgtL3P (Pubitemid 40110059)
18. M Hu J Chen H Lin 2003 Metabolism of flavonoids via enteric recycling: mechanistic studies of disposition of apigenin in the Caco-2 cell culture model J Pharmacol Exp Ther 307 314 321 10.1124/jpet.103.053496 12893842 1:CAS:528:DC%2BD3sXnslGku7k%3D (Pubitemid 37151923)
19. X Jia J Chen H Lin M Hu 2004 Disposition of flavonoids via enteric recycling: enzyme-transporter coupling affects metabolism of biochanin A and formononetin and excretion of their phase II conjugates J Pharmacol Exp Ther 310 1103 1113 10.1124/jpet.104.068403 15128864 1:CAS:528:DC%2BD2cXnt1eqtbk%3D (Pubitemid 39108932)
20. J Chen S Wang X Jia S Bajimaya V Tam M Hu 2005 Disposition of flavonoids via recycling: comparison of intestinal versus hepatic disposition Drug Metab Dispos 33 1777 1784 16120792 1:CAS:528:DC%2BD2MXht1ygu73J
21. EJ Jeong X Jia M Hu 2005 Disposition of formononetin via enteric recycling: metabolism and excretion in mouse intestinal perfusion and Caco-2 cell models Mol Pharm 2 319 328 10.1021/mp0498852 16053335 1:CAS:528: DC%2BD2MXksVyjsrg%3D (Pubitemid 41186408)
22. SW Wang J Chen X Jia VH Tam M Hu 2006 Disposition of flavonoids via enteric recycling: structural effects and lack of correlations between in vitro and in situ metabolic properties Drug Metab Dispos 34 1837 1848 10.1124/dmd.106.009910 16882763 1:CAS:528:DC%2BD28XhtFGqt7jJ (Pubitemid 44771711)
23. M Hu PJ Sinko AL de Meere DA Johnson GL Amidon 1988 Membrane permeability parameters for some amino acids and beta-lactam antibiotics: application of the boundary layer approach J Theor Biol 131 107 114 10.1016/S0022-5193(88)80124-3 3419188 1:CAS:528:DyaL1cXhs1Ghsr4%3D
24. M Hu K Roland L Ge J Chen Y Li P Tyle, et al. 1998 Determination of absorption characteristics of AG337, a novel thymidylate synthase inhibitor, using a perfused rat intestinal model J Pharm Sci 87 886 890 10.1021/js970251e 9649359 1:CAS:528:DyaK1cXjsl2htLs%3D (Pubitemid 28319421)
25. EJ Jeong H Lin M Hu 2004 Disposition mechanisms of raloxifene in the human intestinal Caco-2 model J Pharmacol Exp Ther 310 376 385 10.1124/jpet.103.063925 15020665 1:CAS:528:DC%2BD2cXlsVOjtro%3D (Pubitemid 38812733)
26. Y Adachi H Suzuki AH Schinkel Y Sugiyama 2005 Role of breast cancer resistance protein (Bcrp1/Abcg2) in the extrusion of glucuronide and sulfate conjugates from enterocytes to intestinal lumen Mol Pharmacol 67 923 928 10.1124/mol.104.007393 15598971 1:CAS:528:DC%2BD2MXitlaqtr8%3D (Pubitemid 40365339)
27. B Ebert A Seidel A Lampen 2005 Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists Carcinogenesis 26 1754 1763 10.1093/carcin/bgi139 15917307 1:CAS:528:DC%2BD2MXhtVWnt7fN (Pubitemid 41487991)
28. S Zhang X Wang K Sagawa ME Morris 2005 Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice Drug Metab Dispos 33 341 348 10.1124/dmd.104.002501 15608138 1:CAS:528:DC%2BD2MXisFSgsbs%3D (Pubitemid 40279933)
29. M Bobrowska-Hagerstrand A Wrobel B Rychlik I Ohman H Hagerstrand 2007 Flow cytometric monitoring of multidrug drug resistance protein 1 (MRP1/ABCC1) -mediated transport of 2′, 7′-bis-(3-carboxypropyl)-5-(and-6)- carboxyfluorescein (BCPCF) into human erythrocyte membrane inside-out vesicles Mol Membr Biol 24 485 495 10.1080/09687680701383069 17710652 1:CAS:528:DC%2BD2sXpt1Glu7c%3D (Pubitemid 47290696)
30. L Zhang G Lin B Kovacs M Jani P Krajcsi Z Zuo 2007 Mechanistic study on the intestinal absorption and disposition of baicalein Eur J Pharm Sci 31 221 231 10.1016/j.ejps.2007.04.001 17507208 1:CAS:528:DC%2BD2sXmtVOmsbc%3D (Pubitemid 46818982)
31. BL Abbott 2006 ABCG2 (BCRP): a cytoprotectant in normal and malignant stem cells Clin Adv Hematol Oncol 4 63 72 16562373
32. S Vander Borght L Libbrecht A Katoonizadeh J van Pelt D Cassiman F Nevens, et al. 2006 Breast cancer resistance protein (BCRP/ABCG2) is expressed by progenitor cells/reactive ductules and hepatocytes and its expression pattern is influenced by disease etiology and species type: possible functional consequences J Histochem Cytochem 54 1051 1059 10.1369/jhc.5A6912.2006 16709727 1:CAS:528:DC%2BD28XosFCrt7s%3D (Pubitemid 44298592)
33. AL Cheng CH Hsu JK Lin MM Hsu YF Ho TS Shen, et al. 2001 Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions Anticancer Res 21 2895 2900 11712783 1:CAS:528: DC%2BD3MXovVWgtrg%3D
34. SR Shelnutt CO Cimino PA Wiggins MJ Ronis TM Badger 2002 Pharmacokinetics of the glucuronide and sulfate conjugates of genistein and daidzein in men and women after consumption of a soy beverage Am J Clin Nutr 76 3 588 594 12198004 1:CAS:528:DC%2BD38XmslSntrY%3D
35. L Gu SE House RL Prior N Fang MJ Ronis TB Clarkson, et al. 2006 Metabolic phenotype of isoflavones differ among female rats, pigs, monkeys, and women J Nutr 136 5 1215 1221 16614407 1:CAS:528:DC%2BD28XktFags7g%3D